relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   51 Trials   51 Trials   979 News 
70 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
relatlimab (BMS-986016) / BMS
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
NCT06246916: A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

Recruiting
3
560
US
fianlimab, REGN3767, cemiplimab, REGN2810, LIBTAYO®, relatlimab+nivolumab, Opdualag™
Regeneron Pharmaceuticals
Melanoma
03/27
06/33
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

Recruiting
3
680
Europe, US, RoW
IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG
Immunocore Ltd
Advanced Melanoma
12/26
12/27
NCT06624644: A Trial of LNS8801 with or Without Pembrolizumab in Patients with Refractory Melanoma

Not yet recruiting
2/3
135
NA
LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolumab and relatlimab), Immunotherapy (ipilimumab and nivolumab)
Linnaeus Therapeutics, Inc., Merck Sharp & Dohme LLC
Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
08/28
08/30
NCT05987241: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Recruiting
2/3
1190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, cfDNA or ctDNA Measurement, Cell-Free DNA/Circulating Tumor DNA Measurement, cfDNA/ctdDNA Measurement, cfDNA/ctDNA, cfDNA/ctDNA Measurement, Circulating Cell-Free DNA/Circulating Tumor-Derived DNA Measurement, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
National Cancer Institute (NCI)
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
04/26
04/26
ACTRN12619001308189: In patients with previously untreated early stage triple negative breast cancer, how well does using Nivolumab or Nivolumab + Relatlimab before starting standard chemotherapy, OR starting treatment with Nivolumab and chemotherapy at the same time, help to reduce tumour size before surgery compared?

Recruiting
2
162
 
Breast Cancer Trials, Breast Cancer Trials
Triple negative breast cancer
 
 
2018-002250-79: iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

Not yet recruiting
2
25
Europe
nivolumab, Relatlimab, BMS-986016, Solution for injection/infusion, nivolumab
The Royal Marsden NHS Foundation Trust, Bristol Myers Squibb
Metastatic RAS wild-type colorectal cancer which has previously responded to FOLFIRI chemotherapy and Cetuximab treatment but then progressed, Advanced cancer of the colon or rectum which initially appeared to become smaller on treatment with FOLFIRI and Cetuximab treatment but now has either grown, reappeared or spread, Diseases [C] - Cancer [C04]
 
 
2018-002939-21: Relatlimab, Nivolumab and 5-Azacytidine in Patients with AML Relatlimab, Nivolumab und 5-Azacitidin bei Patienten mit AML

Not yet recruiting
2
30
Europe
Relatlimab, BMS-986016, Concentrate for dispersion for infusion, Concentrate for solution for infusion, Opdivo
Klinikum der Universität München, Bristol-Myers Squibb GmbH
Subjects with Acute myeloid leukemia Patienten mit akuter myeloischer Leukämie, Subjects with relapsed or refractory (r/r) Acute myeloid leukemia (AML) or Patients aged ≥65 years with previously untreated AML who are unfit for or decline standard induction therapy. Patienten mit rezidivierter oder refraktärer akuter myeloischer Leukämie (AML) oder Patienten ≥65 Jahre mit AML, die für eine Standard-Induktionschemotherapie nicht in Frage kommen oder diese ablehnen, Diseases [C] - Cancer [C04]
 
 
2020-002738-34: Cell based treatment in combination with three checkpoint inhibitors for ovarian-, fallopian tube and primary peritoneal cancer. Videnskabeligt forsøg til behandling af æggestokke-, æggeleder og primær bughindekræft med spredning med T-celle terapi i kombination med tre checkpoint inhibitorer

Not yet recruiting
2
18
Europe
Tumor Infiltrating Lymphocytes, Sendoxan, Fludara, Nivolumab, Ipilimumab, Relatlimab, TIL, Infusion, Sendoxan (cyclophosphamide), Fludara (fludarabine phosphate), Opdivo (Nivolumab), Yervoy (ipilimumab), Relatlimab
National Center for Cancer Immune Therapy, National Center for Cancer Immune Therapy
Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer. Metastatisk ovarie-, tuba og primær peritoneal cancer., Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer. Æggestokkekræft, æggelederkræft og primær bughindekræft., Diseases [C] - Cancer [C04]
 
 
2021-002360-51: Study in kidney cancer patients with at least the kidney tumor present and sometimes enlarged lymph nodes in the vicinity of the affected kidney, in which the subjects first receive an immunotherapy treatment, which may consist of either nivolumab alone, or the combination of nivolumab and ipilimumab, or the combination of nivolumab and relatlimab, after which the kidney tumor (and possibly enlarged lymph nodes) is removed.

Ongoing
2
69
Europe
nivolumab, ipilimumab, relatlimab, Solution for injection/infusion, Concentrate for solution for infusion, Solution for injection, Opdivo, Yervoy
Antoni van Leeuwenhoek ziekenhuis, Bristol-Myers Squibb
primary clear cell renal cell cancer at risk for recurrence or distant metastases, heldercellig niercelkanker met hoog risico op terugkerende ziekte of afstandsmetastasen, Diseases [C] - Cancer [C04]
 
 
EAY131-Z1M, NCT06400264: Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Withdrawn
2
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Relatlimab, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
01/23
01/23
FRACTION-GC, NCT02935634 / 2016-002807-24: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed
2
190
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Relatlimab, BMS-986016, BMS-986205, Rucaparib, Rubraca
Bristol-Myers Squibb, Clovis Oncology, Inc.
Advanced Gastric Cancer
05/22
05/22
iSCORE, NCT03867799: Immunotherapy Sequencing in COlon and REctal Cancer

Active, not recruiting
2
25
Europe
Nivolumab, Relatlimab
Royal Marsden NHS Foundation Trust
Metastatic Colorectal Cancer
10/22
09/24
NCT02519322: Neoadjuvant and Adjuvant Checkpoint Blockade

Completed
2
53
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Relatlimab, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
01/23
01/23
NCT05034536: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Recruiting
2
36
US
Pembrolizumab, Keytruda, Infliximab, AVSOLA, Ixifi, Remicade, Renflexis, Placebo, Relatlimab, Nivolumab
Massachusetts General Hospital, Massachusetts Institute of Technology
Metastatic Melanoma
06/25
06/26
RELATIVITY-073, NCT04567615 / 2018-003151-38: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Calendar Jan 2024 - Dec 2024: Data readout from CA224-073 trial for 2L HCC
Active, not recruiting
2
266
Europe, Japan, RoW
Nivolumab, OPDIVO, BMS-936558, Relatlimab, BMS-986016
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
08/23
12/24
CA224-094, NCT04552223: Nivolumab Plus Relatlimab in Patients with Metastatic Uveal Melanoma

Active, not recruiting
2
27
US
Nivolumab, Opdivo, Relatlimab, BMS-986016
Jose Lutzky, MD, Bristol-Myers Squibb, United States Department of Defense
Metastatic Uveal Melanoma
12/24
12/26
CheckMate 142, NCT02060188 / 2013-003939-30: A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Checkmark Data from CheckMate142 trial of nivolumab/Ipilimumab combination in 1L MSI-H or dMMR mCRC
Aug 2022 - Aug 2022: Data from CheckMate142 trial of nivolumab/Ipilimumab combination in 1L MSI-H or dMMR mCRC
Hourglass Dec 2018 - Dec 2018 : Completion of P2 study of BMS-986016 + nivolumab for metastatic CRC
Checkmark In previously untreated patients with MSI-H or dMMR mCRC
Oct 2018 - Oct 2018: In previously untreated patients with MSI-H or dMMR mCRC
More
Active, not recruiting
2
385
Europe, Canada, US, RoW
Ipilimumab, Yervoy, Nivolumab, BMS-936558, Opdivo, Cobimetinib, Cotellic, Daratumumab, Darzalex, BMS-986016
Bristol-Myers Squibb
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
09/24
09/24
RELATIVITY-104, NCT04623775 / 2020-004026-31: A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Hourglass Jan 2024 - Mar 2024 : Early’24 - P2 data readout from CA224-104 trial for 1L stage IV NSCLC
Active, not recruiting
2
468
Europe, US, RoW
Nivolumab, Relatlimab, Carboplatin, Cisplatin, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
01/24
09/25
NCT03642067: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Active, not recruiting
2
59
US
Nivolumab, anti-PD-1, OPDIVO, Relatlimab, BMS-986016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
02/24
02/25
TURANDORELA, NCT06237920: Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Recruiting
2
90
Europe
Nivolumab, Opdivo, Relatlimab, BMS-986016
The Netherlands Cancer Institute, Bristol-Myers Squibb
Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, Urinary Bladder Diseases, Male Urogenital Diseases, Urinary Bladder Neoplasm, Antineoplastics Toxicity
07/26
08/28
IMAGINE, NCT04062656 / 2018-000383-28: Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG

Hourglass Jan 2023 - Dec 2023 : Expiry in EU
Active, not recruiting
2
21
Europe
Nivolumab, Opdivo, relatlimab, BMS-986016 (Bristol Myer´s Squibb), Oxaliplatin, ELOXATIN, Docetaxel, Taxotere, 5-Fluorouracil (5-FU), Adrucil, Folic acid (FA), Leucovorin
University Hospital, Essen, GWT-TUD GmbH
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
03/24
06/25
NCT05077280: A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

Recruiting
2
40
US
stereotactic body radiotherapy, Immunotherapy
California Pacific Medical Center Research Institute
Uveal Melanoma
03/24
03/26
Neo-MCC, NCT06151236: Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting
2
20
RoW
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Merkel Cell Carcinoma
04/26
04/34
NESCIO, NCT05148546 / 2021-002360-51: Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

Recruiting
2
69
Europe
Neoadjuvant nivolumab, Opdivo, Neoadjuvant ipilimumab, Yervoy, Neoadjuvant relatlimab
The Netherlands Cancer Institute, Bristol-Myers Squibb
Renal Cell Carcinoma
04/24
04/29
NCI-2018-01517, NCT03623854: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Completed
2
10
US
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Relatlimab, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
Jonsson Comprehensive Cancer Center, Bristol-Myers Squibb
Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
09/23
09/23
CONGRATS, NCT04095208 / 2019-002332-81: Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Recruiting
2
67
Europe
Association of Nivolumab + Relatlimab, Nivolumab
Institut Bergonié, Bristol-Myers Squibb
Soft Tissue Sarcoma Adult, Advanced Cancer
06/24
12/25
CA224-1065, NCT06288191: Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Not yet recruiting
2
20
NA
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag
Melanoma Institute Australia, Bristol-Myers Squibb
Cutaneous Squamous Cell Carcinoma
09/26
07/36
NCT03607890: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Recruiting
2
42
US
Nivolumab, anti-PD-1, OPDIVO, Relatlimab, BMS-986016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI)
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
10/25
10/25
CA209-1451, NCT06624475: Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

Not yet recruiting
2
30
NA
Nivolumab, Opdivo, Opdualag, Relatlimab and Nivolumab
University of California, San Diego
Basal Cell Carcinoma
12/27
12/27
CA209-8DP, NCT03521830: Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Recruiting
2
57
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Relatlimab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Basal Cell Carcinoma
03/26
03/27
NICHE, NCT03026140 / 2016-002940-17: Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Recruiting
2
268
Europe
Nivolumab, nivolumab (opdivo), Ipilimumab, Ipilimumab (Yervoy), Celecoxib 200mg, Celebrex, BMS-986253, Anti-IL8, BMS-986016, Relatlimab
The Netherlands Cancer Institute, Bristol-Myers Squibb
Colon Carcinoma
12/24
12/24
NCT04953104: Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Recruiting
2
30
US
Diagnostic Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Relatlimab, BMS-986016
M.D. Anderson Cancer Center
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
12/26
12/26
Neopredict-lung, NCT04205552 / 2019-002478-29: Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

Checkmark Data from NEOpredict study for resectable NSCLC
Dec 2022 - Dec 2022: Data from NEOpredict study for resectable NSCLC
Recruiting
2
90
Europe
Nivolumab 10 MG/ML Intravenous Solution, Relatlimab 10 MG/ML Intravenous Solution
University Hospital, Essen
NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
03/25
06/25
AARON, NCT04913922: Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

Recruiting
2
30
Europe
Azacitidine Injection, Nivolumab, Relatlimab
Ludwig-Maximilians - University of Munich
Acute Myeloid Leukemia
03/25
03/26
NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Recruiting
2
80
US
Nivolumab, anti-PD-1 antibody, OPDIVO®, Relatlimab, anti-LAG3 antibody, BMS-986016, Ipilimumab, anti-CTLA4 antibody, Yervoy ®
Dan Zandberg, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/27
09/27
NCT06325683: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recruiting
2
184
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Recurrent Glioblastoma
07/28
07/28
NCI-MATCH, NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Checkmark Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Nov 2019 - Nov 2019: Results from arm Z1D-a subprotocol of the NCI-MATCH study in mismatch repair-deficient non-colorectal cancers
Active, not recruiting
2
6452
US, RoW
Adavosertib, AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775, Afatinib, BIBW 2992, BIBW-2992, BIBW2992, Afatinib Dimaleate, (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate), BIBW 2992MA2, BIBW2992 MA2, Gilotrif, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Defactinib, PF-04554878, VS-6063, Defactinib Hydrochloride, Echocardiography, EC, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Fexagratinib, ABSK-091, ABSK091, AZD4547, FGFR Inhibitor AZD4547, KB-74810, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Laboratory Biomarker Analysis, Larotrectinib, ARRY 470, LOXO 101, LOXO-101, LOXO101, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, PI3K-beta Inhibitor GSK2636771, GSK-2636771, GSK2636771, Radiologic Examination, Radiologic Evaluation, Radiologic Exam, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Sunitinib Malate, SU 011248, SU 11248, SU-011248, SU-11248, SU011248, SU11248, sunitinib, Sutent, Taselisib, GDC-0032, RO5537381, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Ulixertinib, BVD-523, VRT752271, Vismodegib, Erivedge, GDC 0449, GDC-0449, GDC0449, Hedgehog Antagonist GDC-0449
National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
12/25
12/25
CA209-587, NCT04204837 / 2016-002811-16: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

Recruiting
2
61
Europe
Nivolumab, Nivolumab plus Relatlimab
Salzburger Landeskliniken, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Skin
12/26
12/27
NCT05347212: Phase II Trial of Immunotherapy in Patients with Carcinomas Arising from the Renal Medulla

Active, not recruiting
2
30
US
Nivolumab, BMS-936558, Opdivo, Relatlimab, BMS-986016
M.D. Anderson Cancer Center
Carcinomas, Renal Medullary Carcinoma
07/27
07/27
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
REMAIN, NCT06029270: Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recruiting
2
156
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
National Cancer Institute (NCI)
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
04/29
04/29
NCT04326257: Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Active, not recruiting
2
20
US
Nivolumab+Relatlimab, Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538;, Relatlimab: BMS-986016, Nivolumab+Ipilimumab, Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538, Ipilimumab: YERVOY/ BMS-734016/ MDX-010
Dan Zandberg, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck
08/23
08/24
2019-000132-25: A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

Not yet recruiting
1/2
403
Europe
Ipilimumab, Anti-LAG-3 -8ml vial, BMS-734016, BMS-986016, Concentrate for solution for infusion, Solution for injection/infusion
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Melanoma, Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment, Diseases [C] - Cancer [C04]
 
 
2021-000493-29: Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas Relatlimab + nivolumab nei linfomi nella popolazione pediatrica e nei giovani adulti

Ongoing
1/2
99
Europe
Anti-LAG-3, NIVOLUMAB, [BMS-986016], [BMS-936558], Solution for injection/infusion, Concentrate for solution for injection/infusion, Opdivo
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Linfoma di Hodgkin classico e Linfoma Non-Hodgkin ricorrente o refrattario, Hodgkin Lymphoma and Non-Hodgkin Lymphoma Linfoma di Hodgkin e Linfoma Non-Hodgkin, Diseases [C] - Cancer [C04]
 
 
2021-003606-53: Phase 1/2 study of Relatlimab and Nivolumab in Combination with Bevacizumab in First-line HCC Estudio en fase 1/2 de Relatlimab y Nivolumab en combinación con Bevacizumab en CHC de primera línea

Ongoing
1/2
162
Europe
relatlimab - 130 mg/ml, NIVOLUMAB - 10ml vial commercial, Bevacizumab, BMS-986016, BMS-936558, Solution for injection/infusion, Concentrate for solution for infusion, Opdivo (100 mg/10 ml), Avastin 25 mg/ml concentrate for solution for infusion
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Advanced/metastatic hepatocellular carcinoma (HCC) Carcinoma hepatocelular (CHC) avanzado/metastásico, Advanced/metastatic hepatocellular carcinoma (HCC) Carcinoma hepatocelular (CHC) avanzado/metastásico, Diseases [C] - Cancer [C04]
 
 
NCT04611126: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated
1/2
5
Europe
Ipilimumab, Cyclophosphamid, Cyclophosphamide, Fludarabine Phosphate, Tumor Infiltrating Lymphocytes infusion, TILs, Nivolumab, Relatlimab, Relalimab
Inge Marie Svane
Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer
03/24
07/24
PLATFORM, NCT03310619: A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Checkmark PLATFORM trial in combination with JCAR017
Sep 2018 - Sep 2018: PLATFORM trial in combination with JCAR017
Completed
1/2
62
US
JCAR017, Durvalumab, MEDI4736, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Celgene
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
02/23
02/23
NCT04065425: Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Not yet recruiting
1/2
104
NA
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone, BMS-986016, Anti LAG-3, Relatlimab, Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone, BMS-986207, Anti TIGIT
Multiple Myeloma Research Consortium, Bristol-Myers Squibb
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
10/23
10/23
REACTION, NCT03610711: (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Active, not recruiting
1/2
21
US
Nivolumab, Optivo, Relatlimab, anti-LAG3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Gastroesophageal Cancer, Immune Checkpoint Inhibition
12/24
04/25
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Active, not recruiting
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
12/23
12/24
RELATIVITY-048, NCT03459222 / 2018-000058-22: An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Active, not recruiting
1/2
255
Europe, US, RoW
Relatlimab, BMS-986016, Nivolumab, Opdivo, BMS-936558, BMS-986205, Linrodostat, Ipilimumab, Yervoy, BMS-734016
Bristol-Myers Squibb
Advanced Cancer
11/26
11/26
RELATIVITY-106, NCT05337137 / 2021-003606-53: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Calendar Jan 2025 - Dec 2025: Data readout from CA224-106 trial for 1L HCC
Recruiting
1/2
162
Europe, Canada, Japan, US, RoW
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Opdivo, Bevacizumab, Avastin, Placebo
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Carcinoma, Hepatocellular
06/24
12/26
RELATIVITY-020, NCT01968109 / 2014-002605-38: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Hourglass Oct 2020 - Mar 2021 : From trial in combination with Opdivo for melanoma
Checkmark BMS-986016 + Opdivo in melanoma at ASCO 2017
Jun 2017 - Jun 2017: BMS-986016 + Opdivo in melanoma at ASCO 2017
Active, not recruiting
1/2
1499
Europe, Canada, Japan, US, RoW
Relatlimab, BMS-986016, Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3), Nivolumab, Anti-PD-1 (Anti-Programmed-Death-1), BMS-936558, BMS-986213
Bristol-Myers Squibb
Neoplasms by Site
05/24
01/25
RELATIVITY-069, NCT05255601 / 2021-000493-29: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Recruiting
1/2
68
Europe, US, RoW
Relatlimab, BMS-986016, Nivolumab, BMS-936558
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Lymphoma, Non-Hodgkin, Hodgkin Disease
07/28
07/28
NCT02658981: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Completed
1
63
US
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, BMS-936558, Nivolumab, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137, urelumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb
Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
04/22
10/23
NCT04112498: A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Completed
1
24
US
relatlimab, nivolumab, Opdivo, rHuPH20, Enhanze
Bristol-Myers Squibb
Cancer
02/23
02/23
NCT03493932: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Completed
1
21
US
Nivolumab, BMS-986016
National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma
04/23
06/23
NCT03978611: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Terminated
1
11
Europe, Canada, US
Relatlimab, BMS-986016, Ipilimumab
Bristol-Myers Squibb
Melanoma
07/23
07/23
NCT02966548: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Active, not recruiting
1
35
Japan
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Opdivo
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Cancer
08/24
07/25
NCT04697576: Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Recruiting
1
36
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quadrivalent Inactivated Influenza Vaccine, Fluzone Quadrivalent, Fluzone Quadrivalent Influenza Vaccine, QIV, Quadrivalent Influenza Vaccine, Resection, Surgical Resection, Nivolumab + Relatlimab, Opdualag
Carlo Contreras
Clinical Stage I Cutaneous Melanoma AJCC V8, Clinical Stage IA Cutaneous Melanoma AJCC V8, Clinical Stage IB Cutaneous Melanoma AJCC V8, Clinical Stage II Cutaneous Melanoma AJCC V8, Clinical Stage IIA Cutaneous Melanoma AJCC V8, Clinical Stage IIB Cutaneous Melanoma AJCC V8, Clinical Stage IIC Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Metastatic Melanoma
02/26
12/26
CA209-906, NCT03044613: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Active, not recruiting
1
32
US
Nivolumab, Opdivo, Relatlimab, BMS-986016, Anti-LAG3, Carboplatin, Paraplat, Paraplatin, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Paclitaxel, Taxol, Anzatax, Asotax, Bristaxol, Praxel, Taxol Konzentrat, Radiation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
03/25
08/25
NCT06295159: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting
1
90
US
Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Ipilimumab, Yervoy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
03/27
03/27
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
NCT04658147: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Recruiting
1
20
US
Nivolumab, OPDIVO™, BMS 936558, MDX1106, ONO-4538, Relatlimab, BMS-986016, BMS-986016-01, Anti-LAG-3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Hepatocellular Carcinoma
06/25
06/26
RELATIVITY-111, NCT05498480: Study of Relatlimab in Combination With Nivolumab in Chinese Participants

Completed
1
6
RoW
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Opdivo
Bristol-Myers Squibb
Advanced Solid Tumors
01/24
01/24
STELLAR-002, NCT05176483: Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Recruiting
1
1274
Europe, US, RoW
Zanzalintinib, XL092, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab
Exelixis
Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma, Solid Tumor, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
02/26
05/26
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Active, not recruiting
1
16
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Metastatic Melanoma, Metastasis to Brain
06/24
06/25
NCT05629546: Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Not yet recruiting
1
33
US
Cytokine-induced memory-like natural killer cells, ML NK cells, CIML, Relatilmab, Opdualag, Nivolumab
Washington University School of Medicine, Melanoma Research Alliance, Rising Tide Foundation
Advanced Melanoma, Metastatic Melanoma
01/29
10/30
CA209-64R, NCT05170659: Expanded Access for Relatlimab

No Longer Available
N/A
NA
Relatlimab
Bristol-Myers Squibb
 
 

Download Options